First patients enrolled in Phase I clinical trial of Clover Biopharmaceuticals combination vaccine
June 18, 2025
Source: drugdu
74
On June 17, Clover Biopharmaceuticals (02197) issued an announcement announcing that its respiratory syncytial virus (RSV) + human metapneumovirus (hMPV) ± parainfluenzaThe Phase I clinical trial of the PIV3 combined vaccine candidate product has completed the enrollment of the first batch of subjects.
The vaccine candidates involved in this trial include SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), which are developed based on the company's protein trimerization vaccine technology platform.
According to the announcement, the Phase I clinical trial results of Clover Biopharmaceuticals' RSVPreF vaccine candidate product (SCB-1019) announced in October 2024 showed that the vaccine had potentially best-in-class immunogenicity and tolerability characteristics in 70 elderly subjects.
This clinical result provides support for the company's subsequent joint development of hMPV and PIV3 vaccines. The current Phase I clinical trial of the combined vaccine candidate product will enroll up to 192 elderly subjects to evaluate its safety, reactogenicity and immunogenicity.
https://finance.eastmoney.com/a/202506173432628914.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- the first of its kind to achieve the primary endpoint of mid-term analysis in nasopharyngeal carcinoma stage III clinical trials with iza bene July 4, 2025
- Gout treatment welcomes new choices! Changchun High tech’s first domestically approved injection of Fuxinqibai monoclonal antibody for market launch July 4, 2025
- this is the path to carbon neutrality July 4, 2025
- Dizal (Jiangsu) Pharmaceutical Co., Ltd. Voluntary Disclosure of Announcement Regarding Accelerated Marketing Approval of Suvoderm® by the U.S. FDA July 4, 2025
- Rare, Recurrent, and Still a Challenge July 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
